High-dose IL-2 therapy has demonstrated effectiveness in certain cancers, such as melanoma and renal cell carcinoma.378,379 However, its short half-life and side effects, such as vascular leak syndrome, have restricted its use.380 These adverse effects underscore the importance of optimizing the dose to restore T cell functions without triggering excessive activation, which can induce toxicity. The gene discussed is IL2; the disease is melanoma.